484 related articles for article (PubMed ID: 35225948)
1. Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing.
Bahmad HF; Demus T; Moubarak MM; Daher D; Alvarez Moreno JC; Polit F; Lopez O; Merhe A; Abou-Kheir W; Nieder AM; Poppiti R; Omarzai Y
Med Sci (Basel); 2022 Feb; 10(1):. PubMed ID: 35225948
[TBL] [Abstract][Full Text] [Related]
2. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
3. Leading causes of castration-resistant prostate cancer.
Lu M; Lu H; Kong Q
Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
[TBL] [Abstract][Full Text] [Related]
4. Integrating transcriptomics and network analysis-based multiplexed drug repurposing to screen drug candidates for M2 macrophage-associated castration-resistant prostate cancer bone metastases.
Chang J; Jiang Z; Ma T; Li J; Chen J; Ye P; Feng L
Front Immunol; 2022; 13():989972. PubMed ID: 36389722
[TBL] [Abstract][Full Text] [Related]
5. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
6. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
[TBL] [Abstract][Full Text] [Related]
7. Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer.
Semenas J; Dizeyi N; Persson JL
Drug Des Devel Ther; 2013; 7():875-81. PubMed ID: 24009414
[TBL] [Abstract][Full Text] [Related]
8. [Mechanisms of drug resistance in endocrinotherapy for castration-resistant prostate cancer].
Bo B; Guo JB; Liu LR; Wei Q
Zhonghua Nan Ke Xue; 2021 Feb; 27(2):167-171. PubMed ID: 34914335
[TBL] [Abstract][Full Text] [Related]
9. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
10. [COST ANALYSIS OF ANDROGEN DEPRIVATION THERAPY AND DRUGS FOR CASTRATION-RESISTANT PROSTATE CANCER].
Nishizawa K; Hattahara K; Onishi H; Yoshida T
Nihon Hinyokika Gakkai Zasshi; 2021; 112(2):53-57. PubMed ID: 35444081
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
13. Phytoestrogens selective for the estrogen receptor beta exert anti-androgenic effects in castration resistant prostate cancer.
Thelen P; Wuttke W; Seidlová-Wuttke D
J Steroid Biochem Mol Biol; 2014 Jan; 139():290-3. PubMed ID: 23872207
[TBL] [Abstract][Full Text] [Related]
14. Current androgen receptor antagonists under investigation for resistant prostate cancer.
Nigro MC; Mollica V; Marchetti A; Cheng M; Rosellini M; Montironi R; Cheng L; Massari F
Expert Rev Anticancer Ther; 2022 Feb; 22(2):191-202. PubMed ID: 34928193
[TBL] [Abstract][Full Text] [Related]
15. Resetting the Bar of Castration Resistance - Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer.
Shore ND; Morgans AK; Ryan CJ
Clin Genitourin Cancer; 2021 Jun; 19(3):199-207. PubMed ID: 33129718
[TBL] [Abstract][Full Text] [Related]
16. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
Begemann D; Wang Y; Yang W; Kyprianou N
Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
[TBL] [Abstract][Full Text] [Related]
17. FGFR blockade by pemigatinib treats naïve and castration resistant prostate cancer.
Chiodelli P; Coltrini D; Turati M; Cerasuolo M; Maccarinelli F; Rezzola S; Grillo E; Giacomini A; Taranto S; Mussi S; Ligresti A; Presta M; Ronca R
Cancer Lett; 2022 Feb; 526():217-224. PubMed ID: 34861311
[TBL] [Abstract][Full Text] [Related]
18. Comparative pathology of dog and human prostate cancer.
Ryman-Tubb T; Lothion-Roy JH; Metzler VM; Harris AE; Robinson BD; Rizvanov AA; Jeyapalan JN; James VH; England G; Rutland CS; Persson JL; Kenner L; Rubin MA; Mongan NP; de Brot S
Vet Med Sci; 2022 Jan; 8(1):110-120. PubMed ID: 34628719
[TBL] [Abstract][Full Text] [Related]
19. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials.
Ebrahimi S; Hashemy SI; Sahebkar A; Aghaee Bakhtiari SH
Curr Mol Pharmacol; 2021 Oct; 14(4):559-569. PubMed ID: 33357209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
